Clinical Trial Update: Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update indicates completion of a study evaluating rosuvastatin 40 mg on myocardial ischemia in subjects with coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Ischemia

Drugs mentioned

• CRESTOR (Rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Myocardial Ischaemia, Coronary Artery Disease | Phase 3 | Status: COMPLETED